Compare Humana Inc (HUM) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Visa Inc — how do they compare? Humana Inc trades at $433.7 (market cap $46.49B), while Visa Inc trades at $384.35 (market cap $704.20B). The key difference: Visa Inc is far larger — about 15.1× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Visa Inc for 115 Days on average.
| HUM | V | |
|---|---|---|
Market Cap | $46.49B | $704.20B |
Volume | 2,567,704 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $409.85 | $384.14 |
52-Week Low | $163.67 | $295.52 |
Typical Hold Time | 51 Days | 115 Days |
Enterprise Value | $53.84B | $714.78B |
Dividend Yield | 0.91% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
Visa (V) trades at $383.79, up 3.14% today, showing strong momentum near its 52-week high. The stock maintains bullish technical signals with consistent earnings beats and robust fundamentals, including 50.78% net margins and 61.79% ROE. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa at the forefront of payment innovation while maintaining dominant market positioning.
Visa presents a compelling investment case with strong analyst support (85% buy ratings) and a $422.24 price target offering 10% upside. However, elevated valuation multiples (P/E 31.92) and emerging fintech competition require monitoring. The company's consistent execution and AI integration provide growth catalysts, though regulatory scrutiny and payment disruption risks remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
